Protalix BioTherapeutics, Inc. is a biopharmaceutical company. The Company is focused on the development and commercialization of recombinant therapeutic proteins expressed through its proprietary plant cell-based expression system, ProCellEx. Its ProCellEx platform is being used to manufacture approved and marketed product, Elelyso, for the treatment of Gaucher disease. The Company’s ProCellEx is its proprietary platform used to produce and manufacture recombinant proteins through plant cell-based expressions in suspension. Protalix’s development pipeline consists of proprietary versions of recombinant therapeutic proteins that target pharmaceutical markets, including the product candidates, such as PRX-115, a plant cell-expressed recombinant PEGylated Uricase (urate oxidase)- a chemically modified enzyme under development for the potential treatment of severe gout. PRX-119, a plant cell-expressed long action DNase I for the treatment of NETs-related diseases, and others.